Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM
Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM
复制标题
米格列奈治疗可能降低新发 T2DM 患者血浆成纤维细胞生长因子 21 水平
DOI：
10.1016/j.cyto.2011.11.002
复制
发表时间：
2012-02-01
期刊：
影响因子：
3.8
通讯作者：
Li, Ling
中科院分区：
文献类型：
--
作者：
Wang, Bo;Yang, Gangyi;Li, Ling
成纤维细胞生长因子21(成纤维细胞生长因子21)被认为是一种强有力的代谢调节因子。尽管成纤维细胞生长因子-21在调节血糖、血脂和能量平衡方面很重要，但对普通抗糖尿病治疗对血浆成纤维细胞生长因子-21水平的影响知之甚少。本研究的目的是测定初发2型糖尿病(NT2 DM)患者和健康体检者的血浆NO水平，并观察药物干预后循环水平的变化。111名2型糖尿病患者和87名性别、年龄和体重指数匹配的正常糖耐量对照组参与了这项研究。对nT2 DM患者给予米格列奈治疗16周。米格列奈治疗前后用商品化的酶联免疫吸附试验或放射免疫试剂盒检测生化指标、血浆成纤维细胞生长因子-21和胰岛素水平。NT2 DM组空腹血浆成纤维细胞生长因子-21水平高于对照组(3.21±-1.37vs.1.52+/-0.36ug/L，P<0.01)。在nT2 DM患者中，米格列奈治疗16周后空腹血浆成纤维细胞生长因子-21浓度显著降低(3.21±1.37vs.2.79+/-1.14mU/L，P<；0.05)，并伴有明显的糖代谢改善。我们的研究表明，米格列奈治疗降低了血浆成纤维细胞生长因子-21的水平，这种降低可能与改善糖代谢有关。(C)2011爱思唯尔有限公司所有权利
Fibroblast growth factor 21 (FGF-21) has been identified as a potent metabolic regulator. Despite the importance of FGF-21 in the regulation of glucose, lipid and energy homeostasis, much less is known about the effect of common anti-diabetic treatment on the plasma levels of FGF-21. The aim of our study was to measure its plasma levels in patients with new-onset type 2 diabetes mellitus (nT2DM) and healthy subjects, and to assess the changes of its circulating levels after pharmacological interventions. One hundred and eleven patients with nT2DM, and 87 gender-, age- and body mass index (BMI)-matched normal glucose tolerance (NGT) controls participated in the study. The patients with nT2DM were treated with mitiglinide for 16 weeks. Biochemical parameters, plasma FGF-21 and insulin levels were measured by commercial ELISA or RIA kits pre- and post-treatment with mitiglinide. Fasting plasma FGF-21 levels were higher in the nT2DM group than in controls (3.21 +/- 1.37 vs. 1.52 +/- 0.36 mu g/L, P < 0.01). In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after mitiglinide treatment for 16 weeks (3.21 +/- 1.37 vs. 2.79 +/- 1.14 mu g/L, P < 0.05), accompanied by significant amelioration of glucose metabolism. Our study showed that mitiglinide treatment decreased plasma FGF-21 levels, and this decrease might be associated with the amelioration of glucose metabolism. (C) 2011 Elsevier Ltd. All rights